Leerink Partnrs Estimates Tourmaline Bio Q2 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Equities research analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for Tourmaline Bio in a research report issued on Monday, May 5th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings per share of ($0.97) for the quarter. The consensus estimate for Tourmaline Bio's current full-year earnings is ($3.02) per share. Leerink Partnrs also issued estimates for Tourmaline Bio's Q3 2025 earnings at ($1.00) EPS and Q4 2025 earnings at ($0.96) EPS.

TRML has been the subject of a number of other research reports. Lifesci Capital started coverage on shares of Tourmaline Bio in a report on Monday, February 24th. They issued an "outperform" rating and a $58.00 price objective for the company. Wedbush lifted their price target on shares of Tourmaline Bio from $42.00 to $43.00 and gave the stock an "outperform" rating in a research note on Friday, March 14th. Chardan Capital reiterated a "buy" rating and issued a $70.00 price target on shares of Tourmaline Bio in a research note on Monday, May 5th. Finally, HC Wainwright reiterated a "buy" rating and issued a $50.00 price target on shares of Tourmaline Bio in a research note on Monday, May 5th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Tourmaline Bio presently has an average rating of "Buy" and an average price target of $49.33.

Tourmaline Bio Price Performance

Shares of TRML stock traded up $0.83 during trading on Wednesday, reaching $15.93. The company's stock had a trading volume of 41,130 shares, compared to its average volume of 322,961. The company has a market capitalization of $409.24 million, a price-to-earnings ratio of -5.65 and a beta of 2.11. The stock's 50-day moving average price is $15.49 and its 200 day moving average price is $18.65. Tourmaline Bio has a 1-year low of $11.56 and a 1-year high of $29.79.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last announced its quarterly earnings data on Friday, May 2nd. The company reported ($0.89) earnings per share for the quarter, beating analysts' consensus estimates of ($0.91) by $0.02.

Institutional Trading of Tourmaline Bio

Several hedge funds have recently made changes to their positions in the company. Swiss National Bank increased its holdings in shares of Tourmaline Bio by 11.4% in the 1st quarter. Swiss National Bank now owns 22,400 shares of the company's stock valued at $341,000 after purchasing an additional 2,300 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Tourmaline Bio by 2.8% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 65,850 shares of the company's stock valued at $1,002,000 after purchasing an additional 1,791 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Tourmaline Bio by 7.7% in the 1st quarter. Vanguard Group Inc. now owns 1,190,810 shares of the company's stock valued at $18,112,000 after purchasing an additional 84,685 shares in the last quarter. Federated Hermes Inc. increased its holdings in shares of Tourmaline Bio by 13,036.0% in the 1st quarter. Federated Hermes Inc. now owns 121,245 shares of the company's stock valued at $1,844,000 after purchasing an additional 120,322 shares in the last quarter. Finally, SG Americas Securities LLC increased its holdings in shares of Tourmaline Bio by 3.9% in the 1st quarter. SG Americas Securities LLC now owns 36,180 shares of the company's stock valued at $550,000 after purchasing an additional 1,368 shares in the last quarter. Institutional investors and hedge funds own 91.89% of the company's stock.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.